Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Expenditures: 2023-2025

Historic Capital Expenditures for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to -$3,646.

  • bioAffinity Technologies' Capital Expenditures fell 138.75% to -$3,646 in Q3 2025 from the same period last year, while for Sep 2025 it was $60,568, marking a year-over-year decrease of 7.73%. This contributed to the annual value of $79,083 for FY2024, which is 245.31% up from last year.
  • bioAffinity Technologies' Capital Expenditures amounted to -$3,646 in Q3 2025, which was down 127.15% from $13,427 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Capital Expenditures registered a high of $50,786 during Q1 2025, and its lowest value of -$13,442 during Q4 2023.
  • For the 3-year period, bioAffinity Technologies' Capital Expenditures averaged around $14,777, with its median value being $9,410 (2024).
  • In the last 5 years, bioAffinity Technologies' Capital Expenditures soared by 5,468.05% in 2024 and then crashed by 138.75% in 2025.
  • Over the past 3 years, bioAffinity Technologies' Capital Expenditures (Quarterly) stood at -$13,442 in 2023, then surged by 100.01% to $1 in 2024, then slumped by 138.75% to -$3,646 in 2025.
  • Its Capital Expenditures stands at -$3,646 for Q3 2025, versus $13,427 for Q2 2025 and $50,786 for Q1 2025.